HK1210443A1 - Antidotes for factor xa inhibitors and methods of using the same xa - Google Patents

Antidotes for factor xa inhibitors and methods of using the same xa

Info

Publication number
HK1210443A1
HK1210443A1 HK15111214.0A HK15111214A HK1210443A1 HK 1210443 A1 HK1210443 A1 HK 1210443A1 HK 15111214 A HK15111214 A HK 15111214A HK 1210443 A1 HK1210443 A1 HK 1210443A1
Authority
HK
Hong Kong
Prior art keywords
antidotes
inhibitors
factor
methods
same
Prior art date
Application number
HK15111214.0A
Other languages
English (en)
Chinese (zh)
Inventor
Genmin Lu
David R Philllips
Patrick Andre
Uma Sinha
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1210443A1 publication Critical patent/HK1210443A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15111214.0A 2007-09-28 2015-11-13 Antidotes for factor xa inhibitors and methods of using the same xa HK1210443A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US9057408P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
HK1210443A1 true HK1210443A1 (en) 2016-04-22

Family

ID=40481812

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111214.0A HK1210443A1 (en) 2007-09-28 2015-11-13 Antidotes for factor xa inhibitors and methods of using the same xa

Country Status (27)

Country Link
US (8) US8153590B2 (ja)
EP (4) EP2193196B1 (ja)
JP (6) JP5637561B2 (ja)
KR (4) KR102271404B1 (ja)
CN (4) CN101802188B (ja)
AU (6) AU2008304192B9 (ja)
BR (2) BR122022001846B1 (ja)
CA (1) CA2697583C (ja)
CY (2) CY1118482T1 (ja)
DK (3) DK2915564T3 (ja)
ES (3) ES2597436T3 (ja)
FR (1) FR20C1045I2 (ja)
HK (1) HK1210443A1 (ja)
HR (2) HRP20161255T1 (ja)
HU (4) HUE052423T2 (ja)
IL (4) IL203993A (ja)
LT (3) LT3078743T (ja)
MX (1) MX2010003095A (ja)
NL (1) NL301063I2 (ja)
NO (2) NO2019040I1 (ja)
NZ (1) NZ583944A (ja)
PL (3) PL3078743T3 (ja)
PT (3) PT2193196T (ja)
SG (1) SG185263A1 (ja)
SI (3) SI3078743T1 (ja)
WO (1) WO2009042962A2 (ja)
ZA (2) ZA201002039B (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
BRPI0711296A2 (pt) 2006-05-05 2011-08-23 Millennium Phamaceutical Inc inibidores de fator xa
ES2597436T3 (es) * 2007-09-28 2017-01-18 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
EP2364165B1 (en) * 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN104984319A (zh) * 2008-12-19 2015-10-21 巴克斯特国际公司 Tfpi抑制剂和使用方法
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP2316931B1 (de) * 2009-10-30 2016-12-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Polymergekoppelte Peptidasen
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
ES2621809T3 (es) 2010-03-19 2017-07-05 Baxalta GmbH Inhibidores de TFPI y procedimientos de uso
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
EP2665751A1 (en) * 2011-01-19 2013-11-27 Bayer Intellectual Property GmbH Binding proteins to inhibitors of coagulation factors
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
WO2013082210A1 (en) * 2011-11-29 2013-06-06 Perosphere Inc. Anticoagulant reversal agents
EP2814955A1 (en) * 2012-02-14 2014-12-24 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
US20160015793A1 (en) * 2012-02-16 2016-01-21 Portola Pharmacueticals, Inc. Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
ES2612458T3 (es) * 2012-06-14 2017-05-17 Portola Pharmaceuticals, Inc. Procedimiento para purificación de derivados de factor Xa recombinante
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
AU2013375294B2 (en) * 2013-01-24 2018-08-09 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor Xa derivatives
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
AU2014326257B2 (en) * 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
HUE052098T2 (hu) * 2014-05-26 2021-04-28 Academisch Ziekenhuis Leiden Prohemosztatikus fehérjék vérzés kezelésére
WO2016019145A1 (en) * 2014-07-31 2016-02-04 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
EP3750556A1 (en) * 2014-08-20 2020-12-16 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
KR20180123062A (ko) * 2016-02-29 2018-11-14 이리디아, 인크. 정보 저장을 위한 방법, 조성물, 및 장치
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
PE20190661A1 (es) 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019040532A1 (en) * 2017-08-21 2019-02-28 Allele Biotechnology & Pharmaceuticals, Inc. LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE
JP2021502984A (ja) 2017-11-15 2021-02-04 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤
JP2021527435A (ja) * 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
BR112021002675A2 (pt) * 2018-08-14 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. composições farmacêuticas, métodos para preparar as referidas composições e uso das mesmas
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
EP4010379A4 (en) * 2019-08-08 2023-12-20 Alexion Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND ITS DERIVATIVES
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627B (zh) * 2023-03-10 2024-06-07 四川大学 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (ja) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2116764C (en) 1991-09-13 1999-12-07 Amy J. Weiner Immunoreactive hepatitis c virus polypeptide compositions
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
CA2132518A1 (en) 1992-03-20 1993-09-30 Uma Sinha Glycosylation-mediated inhibition of factor x
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AU6673898A (en) 1997-03-07 1998-09-22 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
WO2005088310A2 (en) 2004-03-05 2005-09-22 The Scripps Research Institute High throughput glycan microarrays
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
ES2597436T3 (es) * 2007-09-28 2017-01-18 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN102325880B (zh) 2008-12-19 2014-10-01 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding

Also Published As

Publication number Publication date
JP2020109113A (ja) 2020-07-16
NL301063I2 (nl) 2021-06-23
AU2014210620B2 (en) 2016-05-12
CA2697583C (en) 2016-04-12
US8455441B2 (en) 2013-06-04
DK2193196T3 (en) 2016-11-07
LTPA2020540I1 (lt) 2021-01-11
IL255397A0 (en) 2017-12-31
HUE052423T2 (hu) 2021-04-28
CN102559644A (zh) 2012-07-11
BRPI0816837A2 (pt) 2020-08-18
JP6300885B2 (ja) 2018-03-28
IL203993A (en) 2017-11-30
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
CN103446579A (zh) 2013-12-18
PT3078743T (pt) 2020-07-15
US20140079684A1 (en) 2014-03-20
CN101802188B (zh) 2013-08-21
US8153590B2 (en) 2012-04-10
CY1123504T1 (el) 2021-06-25
AU2014210620A1 (en) 2014-08-28
AU2008304192A2 (en) 2010-04-08
IL255397B (en) 2019-03-31
SI2915564T1 (sl) 2021-03-31
FR20C1045I2 (fr) 2021-08-27
ES2796623T3 (es) 2020-11-27
ZA201406514B (en) 2016-10-26
NO2019040I1 (no) 2019-11-08
KR20100077172A (ko) 2010-07-07
WO2009042962A2 (en) 2009-04-02
DK2915564T3 (da) 2021-02-08
FR20C1045I1 (ja) 2020-10-30
PL2915564T3 (pl) 2021-07-19
SI3078743T1 (sl) 2020-08-31
EP3824902A1 (en) 2021-05-26
HRP20161255T1 (hr) 2016-12-02
EP3078743A1 (en) 2016-10-12
US20120269788A1 (en) 2012-10-25
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
EP2915564A1 (en) 2015-09-09
CA2697583A1 (en) 2009-04-02
IL272926A (en) 2020-04-30
KR20170100071A (ko) 2017-09-01
CN102559644B (zh) 2015-03-25
PT2915564T (pt) 2021-02-09
SG185263A1 (en) 2012-11-29
WO2009042962A9 (en) 2009-09-11
HUE031647T2 (en) 2017-07-28
CN103446579B (zh) 2015-04-22
US9062298B2 (en) 2015-06-23
EP2193196B1 (en) 2016-07-13
US20200276280A1 (en) 2020-09-03
AU2017200212A1 (en) 2017-02-02
US20240082367A1 (en) 2024-03-14
MX2010003095A (es) 2010-04-09
US20150057228A1 (en) 2015-02-26
KR20160025038A (ko) 2016-03-07
IL203993A0 (en) 2011-07-31
AU2008304192B2 (en) 2014-05-15
AU2013205326A8 (en) 2013-06-06
NO2020033I1 (no) 2020-09-23
NL301063I1 (ja) 2020-09-16
HRP20201071T1 (hr) 2020-10-30
EP2915564B1 (en) 2020-11-04
US20090098119A1 (en) 2009-04-16
JP2010539945A (ja) 2010-12-24
WO2009042962A3 (en) 2009-06-04
PL3078743T3 (pl) 2020-11-02
JP6047127B2 (ja) 2016-12-21
LT2193196T (lt) 2016-12-12
EP2193196A2 (en) 2010-06-09
PT2193196T (pt) 2016-10-24
KR102271404B1 (ko) 2021-07-02
BR122022001846B1 (pt) 2022-12-27
JP5637561B2 (ja) 2014-12-10
US20160354449A1 (en) 2016-12-08
US9388401B2 (en) 2016-07-12
JP2022153574A (ja) 2022-10-12
BRPI0816837B1 (pt) 2022-10-18
ZA201002039B (en) 2015-11-25
JP2014218521A (ja) 2014-11-20
CN102533702A (zh) 2012-07-04
ES2849426T3 (es) 2021-08-18
DK3078743T3 (da) 2020-08-10
ES2597436T3 (es) 2017-01-18
NZ583944A (en) 2012-06-29
US8889129B2 (en) 2014-11-18
IL264886B (en) 2020-03-31
US11839646B2 (en) 2023-12-12
KR102069498B1 (ko) 2020-01-23
PL2193196T3 (pl) 2017-07-31
CY1118482T1 (el) 2017-07-12
LTC3078743I2 (lt) 2022-06-10
AU2008304192B9 (en) 2024-02-01
EP3078743B1 (en) 2020-06-24
AU2021218033A1 (en) 2021-09-09
JP2017043632A (ja) 2017-03-02
AU2019204123A1 (en) 2019-07-04
HUE050063T2 (hu) 2020-11-30
HUS2000057I1 (hu) 2021-01-28
JP2018100290A (ja) 2018-06-28
KR101698214B1 (ko) 2017-01-20
US20140044773A1 (en) 2014-02-13
US10675335B2 (en) 2020-06-09
KR20200009131A (ko) 2020-01-29
CN101802188A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
HUS2000057I1 (hu) Az XA faktor inhibitorainak antidótumai és ezek felhasználási módszerei
PT2414517T (pt) Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
IL194891A0 (en) Factor xa inhibitors
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
EP2373658A4 (en) STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
HK1141211A1 (en) Novel seh inhibitors and their use
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
EP2240026A4 (en) NEW SEE INHIBITORS AND THEIR USE
EP2240021A4 (en) NEW SEH-HEMMER AND ITS USE
HK1167406A1 (en) Pyrazolone-derivatives and their use as pd4 inhibitors pd4
EP2240025A4 (en) NEW SEE INHIBITORS AND THEIR USE
EP2309859A4 (en) ENZYME INHIBITORS AND USE THEREOF